Bray Capital Advisors’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | $293K | Hold |
11,028
| – | – | 0.08% | 115 |
|
|
2024
Q3 | $319K | Hold |
11,028
| – | – | 0.08% | 113 |
|
|
2024
Q2 | $309K | Hold |
11,028
| – | – | 0.08% | 113 |
|
|
2024
Q1 | $306K | Hold |
11,028
| – | – | 0.08% | 117 |
|
|
2023
Q4 | $317K | Sell |
11,028
-465
| -4% | -$14.1K | 0.09% | 118 |
|
|
2023
Q3 | $381K | Sell |
11,493
-3,875
| -25% | -$137K | 0.12% | 106 |
|
|
2023
Q2 | $564K | Sell |
15,368
-1,052
| -6% | -$40.9K | 0.17% | 97 |
|
|
2023
Q1 | $670K | Hold |
16,420
| – | – | 0.2% | 95 |
|
|
2022
Q4 | $841K | Sell |
16,420
-5,000
| -23% | -$240K | 0.26% | 86 |
|
|
2022
Q3 | $937K | Buy |
21,420
+2,000
| +10% | +$97.2K | 0.29% | 81 |
|
|
2022
Q2 | $1.02M | Sell |
19,420
-133
| -0.7% | -$6.78K | 0.3% | 82 |
|
|
2022
Q1 | $1.01M | Buy |
19,553
+625
| +3% | +$32.4K | 0.26% | 87 |
|
|
2021
Q4 | $1.12M | Hold |
18,928
| – | – | 0.27% | 81 |
|
|
2021
Q3 | $814K | Hold |
18,928
| – | – | 0.21% | 94 |
|
|
2021
Q2 | $741K | Buy |
18,928
+4,175
| +28% | +$162K | 0.19% | 95 |
|
|
2021
Q1 | $535K | Hold |
14,753
| – | – | 0.15% | 104 |
|
|
2020
Q4 | $543K | Sell |
14,753
-545
| -4% | -$20K | 0.16% | 101 |
|
|
2020
Q3 | $533K | Hold |
15,298
| – | – | 0.19% | 94 |
|
|
2020
Q2 | $475K | Hold |
15,298
| – | – | 0.18% | 96 |
|
|
2020
Q1 | $474K | Sell |
15,298
-738
| -5% | -$25.1K | 0.22% | 86 |
|
|
2019
Q4 | $596K | Buy |
16,036
+6,451
| +67% | +$230K | 0.21% | 91 |
|
|
2019
Q3 | $327K | Buy |
9,585
+385
| +4% | +$14K | 0.13% | 114 |
|
|
2019
Q2 | $378K | Buy |
9,200
+4,319
| +88% | +$172K | 0.15% | 108 |
|
|
2019
Q1 | $197K | Buy |
4,881
+744
| +18% | +$29.8K | 0.08% | 144 |
|
|
2018
Q4 | $171K | Hold |
4,137
| – | – | 0.09% | 154 |
|
|
2018
Q3 | $173K | Hold |
4,137
| – | – | 0.08% | 149 |
|
|
2018
Q2 | $142K | Hold |
4,137
| – | – | 0.07% | 156 |
|
|
2018
Q1 | $139K | Buy |
+4,137
| New | +$142K | 0.06% | 157 |
|
|
2015
Q4 | – | Sell |
-5,518
| Closed | -$164K | – | 252 |
|
|
2015
Q3 | $164K | Sell |
5,518
-105
| -2% | -$3.37K | 0.1% | 132 |
|
|
2015
Q2 | $179K | Sell |
5,623
-590
| -9% | -$19.2K | 0.1% | 137 |
|
|
2015
Q1 | $205K | Buy |
+6,213
| New | +$198K | 0.12% | 134 |
|
Other funds holding PFE
Bray Capital Advisors's PFE Position: Q4 2024 in Review
Bray Capital Advisors held its Pfizer (PFE) position steady in Q4 2024 at 11,028 shares worth $293K. The position accounts for 0.08% of the portfolio, ranked #115.
Bray Capital Advisors first reported a position in PFE in Q1 2015 and has held it in 31 quarters since. The position peaked at $1.12M in Q4 2021. 2,995 funds tracked by Wall St. Rank hold PFE as of Q4 2024.
- Bray Capital Advisors held 11,028 shares of Pfizer worth $293K as of Q4 2024.
- Bray Capital Advisors left its Pfizer share count unchanged in Q4 2024.
- Pfizer made up 0.08% of Bray Capital Advisors's portfolio in Q4 2024, its #115 holding.
- Bray Capital Advisors first reported a position in Pfizer in Q1 2015 and has held it in 31 quarters since.
- Bray Capital Advisors's Pfizer position peaked at $1.12M in Q4 2021.
- 2,995 funds tracked by Wall St. Rank held Pfizer as of Q4 2024.
Based on Bray Capital Advisors's 13F filing for Q4 2024, filed 3 Feb 2025.